The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s arthritis monoclonal antibodies market report forecasts the arthritis monoclonal antibodies market size to grow to $71.66 Billion by 2027, with a CAGR (compound annual growth rate) of more than 7%.

Learn More On The Arthritis Monoclonal Antibodies Market Report 2023 – https://www.thebusinessresearchcompany.com/report/arthritis-monoclonal-antibodie-global-market-report

Arthritis Monoclonal Antibodies Market Size Forecast
The global arthritis monoclonal antibodies market is expected to grow from $49.44 billion in 2022 to $53.81 billion in 2023 at a compound annual growth rate (CAGR) of 8.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The arthritis monoclonal antibodies market is expected to grow from $71.66 billion in 2027 at a CAGR of 7.4%.

Key Arthritis Monoclonal Antibodies Market Driver ­– Increase In The Prevalence Of Arthritis Globally
According to the Centre for Disease Control and Prevention (CDC), in 2020, the adult percentage of arthritis is 23% in the USA which varies by country and osteoarthritis is the most common form of arthritis followed by gout, fibromyalgia, and rheumatoid arthritis. According to WHO, the prevalence of rheumatoid arthritis varies between 0.3% and 1%, and the worldwide estimates of osteoarthritis include 9.6% of men and 18% of women. The increased prevalence of arthritis and the demand for personalized medicine are increasing the demand for the arthritis monoclonal antibody market.

Request for A Sample Of The Global Arthritis Monoclonal Antibodies Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3449&type=smp

Key Arthritis Monoclonal Antibodies Market Trend – Developing Therapeutic Monoclonal Antibody Products
The development of therapeutic monoclonal antibody products is becoming an indispensable tool in the development of the arthritis monoclonal antibody market. Monoclonal antibodies are more efficient than small molecules and peptides in the treatment of arthritis. These are target specific and have good efficiency for disease treatment. These improved treatment options are evident with the launch of a greater number of monoclonal antibody drugs for arthritis.

Arthritis Monoclonal Antibodies Market Segment
1) By Drug: Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, Remsima
2) By Application: Rheumatoid Arthritis, Osteoarthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Fibromyalgia, Other Applications
3) By End-Use: Hopitals, Research Institutes, Other End-Users

Arthritis Monoclonal Antibodies Market Major Players and Strategies

Major players in the arthritis monoclonal antibodies market are Johnson & Johnson, Roche, Novartis, Pfizer Inc., AbbVie Inc., Amgen Inc., Genentech, GSK, AstraZeneca PLC., and Mylan N.V.

In May 2020, AbbVie acquired Allergan for $63 billion. AbbVie is a global biopharmaceutical company whose key therapeutic areas include Immunology and Neuroscience. It is now significantly expanding its revenue base and maintaining its position in immunology by acquiring Allergan. Allergan is a global pharmaceutical leader that manufactures devices, biologics, and surgical and regenerative medicinal products all across the world.

The Arthritis Monoclonal Antibodies Global Market Report 2023 covers regional data on arthritis monoclonal antibodies market size, arthritis monoclonal antibodies market trends and drivers, opportunities, strategies, and arthritis monoclonal antibodies market competitor analysis. The countries covered in the arthritis monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Arthritis monoclonal antibodies refer to a class of sophisticated and useful biologic medicines used to treat rheumatoid arthritis and other immune-mediated inflammatory conditions. They inhibit the inflammatory protein interleukin-6, which reduces arthritis-related joint pain and swelling as well as other inflammation-related symptoms. In order to prevent the body from rejecting the new organ after surgery, they reduce the body’s defence mechanism.

View More Reports Related To The Arthritis Monoclonal Antibodies Market –

Monoclonal Antibodies MAbS Global Market Report 2023

Biosimilar Monoclonal Antibodies Global Market Report 2023

Conjugated Monoclonal Antibodies Global Market Report 2023

Email us at [email protected]

Call us at:

Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708

Follow us on:

LinkedIn: https://bit.ly/3WzV8lZ

YouTube: https://bit.ly/3jiemhz

Global Market Model: https://bit.ly/3Was30B